Natera
Natera, Inc. is a US-based clinical genetic testing firm specializing in non-invasive DNA testing for women's health, cancer, and organ health.
Founded
2004Natera, Inc. is a US-based clinical genetic testing firm specializing in non-invasive DNA testing for women's health, cancer, and organ health.
Natera, Inc., founded in 2004 by Matthew Rabinowitz and Jonathan Sheena, is a clinical genetic testing company headquartered in Austin, Texas. The company's core mission is to transform the management of disease worldwide through genetic insights. Natera specializes in non-invasive, cell-free DNA (cfDNA) testing technology, focusing on women's health, oncology, and organ health. Their proprietary technology integrates advanced molecular biology techniques with sophisticated bioinformatics software, enabling the detection of genetic anomalies from a single molecule in a blood sample.
Notable figures associated with Natera include its founders, Matthew Rabinowitz and Jonathan Sheena. The company has attracted significant investment and is publicly traded on the Nasdaq under the ticker symbol NTRA. Key achievements include the development of groundbreaking cfDNA tests and the operation of CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments. Natera's impact is profound, offering critical genetic insights that aid in early detection and management of various health conditions, thereby improving patient outcomes globally.
Companies similar to Natera include Invitae, Fulgent Genetics, Cradle Genomics and 23andMe.
Natera was founded in 2004.
Natera's headquarters is located in Austin, TX, US.
Natera's most recent funding round was for $250M (USD) in September 2023.
As of Sep 7, 2023, Natera has raised a total of $1.2B (USD).
Natera has 3,018 employees as of Feb 6, 2024.
Cradle Genomics
